Introduction {#S1}
============

*Leishmania (Leishmania) amazonensis* is one of the etiological agents of the tegumentary leishmaniasis in Latin America ([@B1]) and occurs more frequently in the Amazon forest region ([@B2]). Infection with *Leishmania amazonensis* and other members of the Mexican *Leishmania* complex may lead to various clinical manifestations, and even with standard chemotherapy, some of them are relatively difficult to control ([@B1]). *L. amazonensis* is the etiological agent of cutaneous diffuse leishmaniasis ([@B2]), and in some cases, the infection may result in visceral leishmaniasis ([@B3]).

Infections with *L. amazonensis* differ from other *Leishmania* species infections due to their ability to suppress the activation and functions of immune cells, like macrophages, dendritic cells, and CD4^+^ T cells ([@B4]). Due to the susceptibility to infection with *L. amazonensis*, BALB/c mice have been used in several pre-clinical studies in order to understand the mechanisms of parasite's evasion of the host immune defense system ([@B5]). To date, no ideal therapy for cutaneous leishmaniasis has been identified, and no universally accepted therapeutic regimen and approved vaccines are available. These limitations regarding an effective therapy highlight the need to develop new therapeutic strategies against cutaneous leishmaniasis.

Several studies have demonstrated that mesenchymal stromal cells (MSCs) can stimulate endogenous repair of injured tissues, modulate immune responses, and are recruited to inflammation sites through chemotactic mechanisms not completely understood ([@B6]). The MSCs promote repair and regeneration of damaged tissues by paracrine activity, through secretion of growth factors, cytokines, and chemokines. These factors can inhibit apoptosis, stimulate proliferation, promote vascularization, and modulate the immune response, promoting tissue regeneration ([@B7]). Stem cell therapy showed beneficial effects in cardiomyopathies ([@B8], [@B9]), including experimental chagasic cardiomyopathy caused by *Trypanosoma cruzi* protozoan ([@B10]--[@B12]). Therefore, since MSCs mitigate the progression of Chagas Disease ([@B10]--[@B12]), we hypothesized that it may also act on another parasites, such as *L. amazonensis*.

Leishmaniasis caused by *L. amazonensis* is an immunopathology with direct participation of CD4^+^ T cells in lesion development ([@B13]). Improving the lesion physiology due to the suppressive ability of MSCs to inhibit the formation of harmful effector T cell responses could be a strategy to treat leishmaniasis. There is no *in vivo* study evaluating the effect of MSC against leishmaniasis. Two different *in vitro* studies were performed using MSC, macrophages and *Leishmania major* to investigate phagocytosis. The first one demonstrated that macrophages pre-educated with MSC using trans-well system reduced phagocytosis of *L. major* ([@B14]). The other study from the same group demonstrated that cocultured macrophages with MSC pre-stimulated by soluble *L. major* antigens reduced yeast phagocytosis ([@B15]). However, the coculture of infected macrophage with MSC was not carried out.

In our work, we attempted to test the effects of bone marrow-derived MSC as an *in vitro* and *in vivo* therapy in a murine model of cutaneous leishmaniasis induced by *L. amazonensis*.

Materials and Methods {#S2}
=====================

Animals {#S2-1}
-------

BALB/c mice originally obtained from the animal facilities of Universidade Federal Fluminense (UFF) were maintained in our own facilities with water and food *ad libitum*. Animals aged between 6 and 8 weeks were used. All experimental protocols used in this work were approved by the Ethical Committee for Experimental Animal Use established in the Instituto de Biofísica Carlos Chagas Filho---UFRJ under reference code CEUA IBCCF 157.

Parasites {#S2-2}
---------

The parasites used in the experiments presented in this paper were *L. amazonensis* (MHOM/BR/00/Josefa strain) obtained by puncture of amastigotes from the lesion of infected BALB/c mice. The promastigotes were maintained at 26°C in M199 medium (Difco, NJ, USA) containing 10% fetal bovine serum (FBS; Gibco, NM, USA) until the fifth passage in culture to perform infection experiments. Infections were carried out with stationary phase culture, between the fourth and fifth days of culture.

Preparation of MSC {#S2-3}
------------------

Bone marrow cells were obtained from tibia and femurs of five BALB/c mice (20--25 g weight, with the age of 2 months), which were anesthetized with intravenous ketamine (25 mg/kg) and xylazine (2 mg/kg). Tissues were collected, rinsed with phosphate-buffered saline (PBS), transferred to a Petri dish, and cut into small pieces (approximately 0.2--0.8 cm^2^). The dissected pieces were washed with PBS, cut into smaller fragments, and subsequently digested with type I collagenase (1 mg/mL in DMEM/10 mM HEPES) for 30--40 min at 37°C. Any gross remnants that persisted after collagenase digestion were poured off between 1 and 3 min, and the supernatant was transferred to a new tube containing fresh medium and centrifuged at 400 × *g* for 10 min at 25°C. The pellets were resuspended in 3.5 mL Dulbecco's Modified Eagle's Medium (DMEM; Invitrogen, CA, USA) containing 1% penicillin and streptomycin, with concentration of 5,000 IU/mL and 5,000 µg/mL, respectively (Gibco, NM, USA), 20% of inactivated FBS (Invitrogen, CA, USA) and 15 mM HEPES (Sigma, MO, USA), seeded in T25 flasks (4 mL per flask) and incubated at 37°C in a humidified atmosphere containing 5% CO~2~. On day 3 of culture, the medium was changed, and non-adherent cells were removed. Adherent cells exhibited similar proliferation rates and, upon reaching 80% confluence, they were passaged with a 0.25% trypsin-EDTA solution (Gibco, NM, USA) and maintained in DMEM with 10% FBS (complete medium). Approximately 1 × 10^6^ cells were characterized as MSCs at the third passage according to the consensus of the International Society of Cell Therapy ([@B16]).

Characterization of MSCs {#S2-4}
------------------------

Mesenchymal stromal cells were further characterized by their ability to differentiate into osteocytes, chondrocytes, and adipocytes ([@B16], [@B17]). Osteogenic differentiation was induced by culturing MSCs for up to 3 weeks in DMEM 10% FBS and 15 mM HEPES (Sigma, MO, USA), supplemented with 10^−5^ mM/L dexamethasone (Sigma, MO, USA), 5 µg/mL ascorbic acid 2-phosphate (Sigma, MO, USA), and 10 mM/L β-glycerolphosphate (Sigma MO, USA) ([@B17]). To observe calcium deposition, cultures were stained with Alizarin Red S (Nuclear, SP, Brazil). To induce adipogenic differentiation, MSCs were cultured with 10^−8^ M dexamethasone (Sigma, MO, USA), 2.5 µg/mL insulin, and 50 µg/mL indomethacin (Sigma, MO, USA) ([@B18]). Adipocytes were easily discerned from undifferentiated cells by phase-contrast microscopy. To further confirm their identity, cells were fixed with 4% paraformaldehyde with PBS and stained with Oil Red (Sigma, MO, USA) on day 21 of adipogenic differentiation. To induce chondrogenic differentiation, MSCs were cultured in DMEM supplemented with 10 ng/mL TGF-β1 (Sigma, MO, USA), 50 nM ascorbic acid 2-phosphate (Sigma, MO, USA), and 6.25 mg/mL insulin for 3 weeks. To confirm differentiation, cells were fixed with 4% paraformaldehyde in PBS for 1 h at RT and stained with Alcian Blue pH 2.5 ([@B19]) for detecting chondroblast secreted cell matrix (with chondrogenic differentiation) (data not shown).

Flow cytometry was performed using commercially available antibodies on FACSCalibur (Becton Dickinson, San Jose, CA, USA) following standard procedures. Cells were plated in 96-well plates and then centrifuged for 4 min at 300 × *g*, 4°C. Afterward, 10 µL of anti-CD16/32 antibody were added in cells (Fc receptor blocker), remaining for 15 min at 4°C. At the end of incubation, the cells were washed with PBS (100 µL/well), the plate was centrifuged at 300 × *g* for 4 min at 4°C and the supernatant was discarded. Subsequently, the cells were incubated with 10 µL of solution containing the anti-CD11b/FITC, anti-Sca-1/APC, anti-CD44/Pecy5, anti-CD45/PE, anti-CD49/PE, and anti-CD34/EFluor660 for 30 min at 4°C under light protection. Thereafter, the cells were washed with 100 µL of PBS and again centrifuged at 300 × *g* for 4 min at 4°C. After discarding the supernatant, the cells were resuspended in 200 µL of 1% PFA and transferred to FACS tubes containing 100 µL of PBS. The cells were analyzed using the FACSCalibur BD flow cytometry apparatus (BectonDickenson). Data were analyzed using FlowJo software 8.7 (Figures [S1](#SM1){ref-type="supplementary-material"}A--F in Supplementary Material). The respective antibody isotypes of the abovementioned antibodies or samples of unlabeled cells were used as controls. Undifferentiated population of MSCs was used in all experiments.

Peritoneal Washing {#S2-5}
------------------

Syringes containing 5 mL of RPMI (Gibco, NM, USA) medium were injected in the peritoneal cavity of BALB/c mice to obtain the macrophages. The medium containing the macrophages was withdrawn from the cavity and cells were counted with Tripan blue and transferred to a 24-well plate at the concentration of 5 × 10^5^ cells per well. The cells were incubated for 1 h at 37°C and 5% of CO~2~ for adhesion of macrophages to the plate. Thereafter, the plate was washed with warm PBS three consecutive times to remove the non-adherent cells, and then, 400 µL of RPMI with 10% of FBS supplemented with glutamine, pyruvate, and non-essential amino acids were added. After 24 h, the wells were washed again with PBS to remove B1 lymphocytes and 300 µL of RPMI with 10% of supplemented FBS were added.

*In Vitro* Infection and Treatment of Infected Macrophages with MSC {#S2-6}
-------------------------------------------------------------------

The peritoneal cells were plated in a concentration of 5 × 10^5^ cells per well. The infection was performed with 2.5 × 10^6^ of *L. amazonensis* per well (ratio of 5:1) during 4 h with stationary promastigotes of *L. amazonensis*. After the infection time, the wells were washed with PBS and 5 × 10^4^ MSC were added to some wells and left for 48 h at 37°C and 5% of CO~2~. The plate was washed again with warm PBS three times. Finally, the plate was fixed and stained with a fast panoptic kit (Laborclin, RJ, Brazil). The infection was analyzed by optical microscopy (CX31, Olympus, Japan).

*In Vivo* Infection and MSC Therapy {#S2-7}
-----------------------------------

One week after being received from the UFF, the animals were infected by subcutaneous route with 20 µL of PBS containing 2 × 10^6^ promastigotes of *L. amazonensis* on the right rear footpad. 7 and 37 days after infection, animals were treated with 1 × 10^5^ MSCs, either intralesional (i.l.) (into the plantar cushion of the right rear footpad) or intravenously (i.v.), through the external jugular vein. Control animals received the same volume (50 µL) of PBS by i.l. or i.v. routes. MSCs (1 × 10^5^ cells) were administered in 50 µL by intravenous (i.v.) injection or 20 µL by intralesional (i.l.) injection. The animals were sedated with sevoflurane (Sevorane^®^, Abbot, IL, USA) for i.v. or i.l. administration.

Clinical Profile (Lesion and Parasite Load) {#S2-8}
-------------------------------------------

The lesion growth was weekly monitored with a pachymeter in millimeter scale (Mitutoyo, Japan). The measurement of the uninfected footpad was then deducted. Forty-two days after infection, mice were euthanized and the infected footpad of each animal was removed, placed in a 70% alcohol solution for 1 min, and individually weighed. Additionally, the right popliteal lymph node was removed and placed in a vial with 1 mL of M199 medium. Footpads homogenates were obtained by manual maceration of the lesions with addition of 1 mL of M199 medium and, after sedimentation of the heavier particles, 10 µL of the supernatants were recovered and resuspended in 990 µL of medium, thereby obtaining a pre-dilution of 1:100. The number of parasites in the footpads, spleens, lymph nodes, and livers was determined by the limiting dilution assay (LDA). The macerates were diluted into 96-well culture plates (Jet Biofil, China) and incubated at 26°C for 15 days. Promastigotes cultures were observed with an optical microscope (Olympus, Japan) and the last well containing promastigotes was observed and noted (limiting dilution assay).

Detection of Markers, Transcription Factor, and Intracellular Cytokines by Flow Cytometry Method (FACS) of T Cells {#S2-9}
------------------------------------------------------------------------------------------------------------------

The cells of the macerate of the popliteal lymph node were quantified by counting in a Neubauer chamber (2 × 10^6^ cells per well in 24-well plates) to characterize T cells (CD4, CD8), regulatory T cells (CD4, CD25, FoxP3), and production of cytokines (IL-10, IFN-γ). The plates were centrifuged at 300 × *g* for 4 min. 100 µL of FACS buffer (PBS in 10% FBS) were added to the pellet and the cells were centrifuged again.

In the plate for characterization of regulatory T cells, non-specific-labeling blockage with anti-FCR (1:100) incubation was done for 5 min, followed by surface labeling with anti-CD4/Pecy7 (1:200) and anti-CD25/APC (1:200) for additional 30 min. The volume was made up to 200 µL in FACS buffer; the cells were centrifuged, followed by fixation in a kit fixation buffer (eBioscience) during 1 h. Then, the cells were washed and 100 µL of permeabilization buffer (eBioscience) kit were added to the pellet and incubated for 1 h, followed by centrifugation. Then, the cells were incubated with anti-FCR for 20 min and intracellular labeling was performed with anti-FoxP3/AlexaFluor 488 (1:50) incubating for 30 min. The cells were washed in permeabilization buffer and resuspended in FACS buffer for flow cytometry analysis (FACSCalibur system).

In the cytokine characterization plate, the cells were stimulated during 4 h with PMA (phorbol 12-myristate 13-acetate) (20 ng/mL), ionomycin (1000 ng/mL), and monensin (5 µL/mL) to inhibit cytokines secretion. Following the stimulation, the cells were washed in FACS buffer. Blockage of non-specific labeling with anti-FCR (1:100) incubation was done for 5 min, followed by surface labeling with anti-CD4/PeCy7 (1:200), anti-CD8/FITC for 30 min. The volume was filled to 200 µL in FACS buffer; the cells were centrifuged and further washed in FACS buffer. 100 µL of 1% paraformaldehyde was added to the pellet for fixation, which was left for 1 h incubation, followed by centrifugation. 100 µL of permeabilization buffer were added to the pellet (PBS and 0.1% saponin) and left for 1 h incubation, followed by centrifugation. The cells were incubated with anti-FCR for 5 min and then intracellular labeling was performed with anti-IL-10-PE (1:60) and anti-IFN-γ/APC (1:60) incubating for 30 min. The cells were washed in permeabilization buffer and resuspended in FACS buffer for flow cytometry (FACSCalibur system). The results were analyzed using software SUMMIT V4.3 Build 2445.

Detection of Cytokines by the Enzyme-Linked Immunosorbent Assay (ELISA) Method {#S2-10}
------------------------------------------------------------------------------

Concentrations of the cytokines present in the footpad homogenate supernatants were determined by the ELISA using commercial kits (BD OptEIA) according to the datasheet instructions. Recombinant murine IL-10, IL-4, and TGF-β were used to generate the standard curves. The detection limits for these tests are 31.3 pg/mL for TGF-beta and IL-10 and 15.72 pg/mL for IL-4.

Statistical Analysis {#S2-11}
--------------------

No formal sample size calculation was performed to determine the numbers of animals per group; the sample size was based on the experience of our laboratory in previous studies using this model of cutaneous leishmaniasis ([@B20]). To compare *in vitro* data, Student's *t*-test was used. Two-way ANOVA following Bonferroni's *post hoc* test was used to compare all other parameters. *P*-values of 0.05 or less were considered meaningful. For *in vivo* experiments, we compared both groups, i.l. and i.v. This comparison between i.l. and i.v. was carried out besides of the differences between the two treatment protocols, according to the reviewer suggestion. All tests were analyzed using the statistical software package GraphPad Prism v6.0 (GraphPad Software, La Jolla, CA, USA).

Results {#S3}
=======

Characterization of Bone Marrow MSCs {#S3-1}
------------------------------------

Mesenchymal stromal cells adhered to plastic under standard tissue culture conditions and were able to differentiate into mesenchymal lineages, including osteocytes, chondrocytes, and adipocytes under *in vitro* conditions (data not shown). Additionally, MSCs expressed cell surface markers, such as: CD44, CD49 and Sca-1, bud did not express CD11b, CD45 and CD34 ([@B6]). We observed that in the third passage of the culture, most cells express CD44 (95%) (Figure [S1](#SM1){ref-type="supplementary-material"}A in Supplementary Material), CD49 (88.9%) (Figure [S1](#SM1){ref-type="supplementary-material"}B in Supplementary Material), and Sca-1 (91.2%) (Figure [1](#SM1){ref-type="supplementary-material"}C in Supplementary Material) markers, and only a small fraction expressed CD11b (0.7%) (Figure [S1](#SM1){ref-type="supplementary-material"}D in Supplementary Material), CD45 (0.6%) (Figure [S1](#SM1){ref-type="supplementary-material"}E in Supplementary Material), and CD34 (0.4%) (Figure [S1](#SM1){ref-type="supplementary-material"}F in Supplementary Material) markers. Figure [S1](#SM1){ref-type="supplementary-material"}G in Supplementary Material represents the cell profile.

Coculture with MSC Increased Parasite Load of Macrophages {#S3-2}
---------------------------------------------------------

We decided to evaluate the effect of MSC *in vitro* on infected macrophages using coculture of macrophages and MSCs. Figure [1](#F1){ref-type="fig"}A shows macrophages infected with *L. amazonensis* and Figure [1](#F1){ref-type="fig"}B shows macrophages infected with *L. amazonensis* in coculture with MSC. The presence of MSC increased the parasite load on macrophages *in vitro*, with a meaningful difference in terms of total number of amastigotes between infected macrophages (MΦ + Leish) and infected macrophages in coculture with MSC (MΦ + Leish + MSC) (Figure [1](#F1){ref-type="fig"}C). The same was observed regarding the total number of *Leishmania* by the amount of infected macrophages (Figure [1](#F1){ref-type="fig"}D). This result suggests that MSC induced an increase of susceptibility of the macrophages in the *in vitro* infection.

![Macrophages infected with *Leishmania amazonensis*, cocultured with mesenchymal stromal cell (MSC) or not. **(A)** Macrophages infected with *L. amazonensis*; **(B)** coculture of infected macrophages with *L. amazonensis* and MSCs; **(C)** total number of amastigotes; **(D)** number of amastigotes per cell. Macrophages were isolated from peritoneal cavity and plated at 5 × 10^5^ cells per well. After 24 h cells were infected with 2,5 × 10^6^ *L. amazonensis* per well for 4 h and then washed. MSCs were plated at 1 × 10^4^ concentration per well. The plate was stained 48 h after the infection with fast panoptic kit. The *Leishmania* were counted on the optical microscope, Olympus CX31, at 100× magnification; Photo taken from inverted microscope Olympus BX51 at 40× magnification with the program Cell F 3.1. Fluorescence Microscope, OLYMPUS BX51. *N* = 1; triplicate average of one experiment (*P* ≤ 0.05). Results representative of three experiments.](fimmu-08-00893-g001){#F1}

Treatment with MSC by i.v. Route Showed a Non-Protective Effect on Infection by *L. amazonensis* {#S3-3}
------------------------------------------------------------------------------------------------

To assess the efficacy of MSC treatment *in vivo*, BALB/c mice were infected and treated as described in the methodology. In relation to the lesion growth, treatment with MSCs by intravenous or intralesional route did not induce protection when compared with the controls (Figure [2](#F2){ref-type="fig"}A). However, treatment with MSC by intravenous route increased the parasite load in the infected footpad in relation to control (PBS i.v.) and other groups (PBS i.l. and MSC i.l.) (Figure [2](#F2){ref-type="fig"}B). The treatment with MSC by intralesional route did not affect the parasite load in comparison with control (PBS i.v.) (Figure [2](#F2){ref-type="fig"}B). There is no significant difference between any groups in terms of popliteal lymph nodes parasite load (Figure [2](#F2){ref-type="fig"}C). These results show that the use of i.v. therapy with MSC aggravated the infection caused by *L. amazonensis* at the infection site.

![Effect of mesenchymal stromal cell (MSC) treatment on clinical profile. **(A)** Lesion growth during 42 days; **(B)** Parasite load of the footpads; **(C)** Parasite load of the popliteal lymph nodes. BALB/c mice were infected with 2 × 10^6^ of *Leishmania amazonensis* at the right footpad (day 0). At day 7 they received the first dose of treatment (1 × 10^5^ MSC cells). Animals from the MSC i.v. group were treated with cell injection (50 µL) in the external jugular vein. phosphate-buffered saline (PBS) i.v. animals received injection of PBS (50 µL) into the external jugular vein, while the MSC i.l. group was treated with cell injection (20 µL) at the same site of infection as so the PBS i.l. group, that received a injection (20 µL) of PBS. 30 days after the first dose (day 37), the second dose was applied in each group. The lesion growth in the footpad was measured weekly by pachymetry (in millimeter), discounting the measurement of the uninfected footpad. After 42 days, the animals were euthanized and footpads and popliteal lymph nodes were removed and macerated for the parasite load analysis by the limiting dilution assay (LDA) (\*) *P* ≤ 0.05; not significant (NS); *N* = 5; results representative of three experiments.](fimmu-08-00893-g002){#F2}

Evaluation of Regulatory T Cells in the Spleen {#S3-4}
----------------------------------------------

Based on the capacity of MSC therapy act systemically, we investigated the cell and cytokine profiles in the spleen. We evaluated the percentage of effector T cells (CD4^+^ CD25^+^ FoxP3^−^) and Treg cells (CD4^+^ CD25^+^ FoxP3^+^) by quantification of CD25^+^ and FoxP3^+^ markers in CD4^+^ T cells. In both groups, the percentages of effector T cells were similar (Figure [3](#F3){ref-type="fig"}A). However, there were increases of Treg cells in intravenous MSC treated animals when compared to PBS i.v. group, which was not observed when comparing MSC i.l. group to its control (PBS i.l.) (Figure [3](#F3){ref-type="fig"}B). It could be observed, by comparing intravenous versus intralesional treatment, that intralesional groups PBS i.l. and MSC i.l. showed an increase in relation to PBS i.v.; however, no difference was noted when compared with MSC i.v. These results suggest that Treg alone was not associated to an increase of parasite load.

![Percent of effector T cells and regulatory T cell in the spleen. The cells were collected from the spleen macerate. The percentage of CD4^+^ T cells in the spleens of the groups was evaluated through the CD4^+^ marker by flow cytometry (FACSCalibur BD), using antibody (BD), following the supplier's instructions. CD4^+^ T cells, (CD4^+^ CD25^+^ FoxP3^−^) **(A)**, Treg (CD4^+^ CD25^+^ FoxP3^+^) **(B)** Dot plot of CD25 and FoxP3 staining gated on CD4^+^ spleen cells **(C)**. Data are presented as significant and ± Standard Deviation for each group. Representative graph of 2 experiments. \*(*P* \< 0.05) indicates significant statistical difference.](fimmu-08-00893-g003){#F3}

Treatment with MSC by i.v. Route Increased the Percentage of IL-10 Producing T Cells {#S3-5}
------------------------------------------------------------------------------------

We evaluated the percentage of IFN-γ and IL-10 produced by CD4^+^ and CD8^+^ T cells in the spleen. We observed the increase of CD4^+^ and CD8^+^ T cells producing IL-10 in mice treated with MSC i.v. in comparison to PBS i.v., but not with MSC i.l. in comparison to PBS i.l. (Figures [4](#F4){ref-type="fig"}C,G). When we compared intralesional versus intravenous treatment, it was observed that IL-10 produced by T CD4^+^ in MSC i.v. was increased in relation to PBS i.l. and MSC i.l., and no difference was observed between PBS i.v. against PBS i.l. and MSC i.l. The production of IL-10 by TCD8^+^ was increased in MSC i.v. in comparison to PBS i.l., but not in relation to MSC i.l. At the same time, we observed a reduction of IFN-γ produced by TCD8^+^, but not by CD4^+^ T cells, in animals treated with MSC i.v. in comparison to PBS i.v. No difference was observed on mice treated with MSC i.l. (Figure [4](#F4){ref-type="fig"}). No difference was observed in terms of production of IFN-γ by TCD4^+^ between the intravenous and intralesional treatments. However, in the production of IFN-γ by TCD8^+^, we observed a decrease of production of PBS i.l. and MSC i.l. in comparison to PBS i.v. and no difference was observed when compared MSC i.v. against PBS i.l. and MSC i.l. Altogether, the production of IL-10 by T CD4^+^ and T CD8^+^ cells in the group treated with MSC by i.v. is probably the major mechanism associated to increase the susceptibility to infection.

![Detection of cytokines produced by CD4^+^ T cells and CD8^+^ T cells in the spleen. The cells were collected from the spleen macerate. Cells were analyzed by flow cytometry (FACS CALIBUR BD) for expression of CD4^+^ lymphocytes cytokine-producers of IFN-γ **(A)** and IL-10 **(C)** and of CD8^+^ lymphocytes cytokine-producers of IFN-γ **(E)** and IL-10 **(G)**. Results were shown as percentage of positive cells for these markers. Dot plot of IFN-γ **(B)** and IL-10 **(D)** staining gated on CD4^+^ spleen cells. Dot plot of IFN-γ **(F)** and IL-10 **(H)** staining gated on CD8^+^ spleen cells. Data are presented as significant and ± Standard Deviation for each group. Representative graph of 2 experiments. \*(*P* \< 0.05) indicates statistically significant difference.](fimmu-08-00893-g004){#F4}

Evaluation of Cytokine Production in the Footpad {#S3-6}
------------------------------------------------

After observing the deleterious effect of MSC by the i.v. route and the increased production of IL-10 by CD4^+^ T cells and CD8^+^ T cells, we evaluated the profile of pathogenic cytokines in the lesion by ELISA on footpad homogenate. There was a significant increase in IL-10 (Figure [5](#F5){ref-type="fig"}A) in the groups treated with MSC by i.v. when compared to the group treated with PBS by i.v., a fact that was not observed in the MSC i.l. group in relation to its controls (PBS i.l.). No difference was noted between intralesional and intravenous treatments (Figure [5](#F5){ref-type="fig"}A). This result suggests the importance of IL-10 only in i.v. treatment. There were no meaningful differences between the treated groups when compared to their controls in terms of concentration of TGF-β (Figure [5](#F5){ref-type="fig"}B) and IL-4 (Figure [5](#F5){ref-type="fig"}C).

![Analysis of cytokines in footpad. After euthanasia, the infected footpad of each animal was removed and a homogenate of the lesion was obtained by manual maceration. The concentrations of IL-10 **(A)**, TGF-β **(B)**, and IL-4 **(C)**. DC cytokines present in the homogenate's supernatants were determined by enzyme-linked immunosorbent assay using a BD commercial kits, according to the manufacturer's instructions. Expressed in picograms per milligram of tissue. \* (*P* \< 0.05); (\#) Not determined; *N* = 5; representative result of two experiments.](fimmu-08-00893-g005){#F5}

Discussion {#S4}
==========

*Leishmania amazonensis* is a member of the *Leishmania mexicana* complex and an etiological agent of diffuse cutaneous leishmaniasis (DCL) ([@B21]). Patients with DCL have some clinical signs, such a low rate of T-cell stimulation *in vitro* and fail in skin hypersensitivity tests using *Leishmania* antigens (negative Montenegro reaction), although some patients continue to respond to other antigens, such as tuberculin and lepromin ([@B21]). According to the Brazilian Ministry of Health, since 2005, the presence of *L. amazonensis* has been demonstrated in all Brazil regions ([@B2]), thus raising the concern about this infection.

As this form of the disease is refractory to conventional treatment, the search for new therapies is essential to fight this pathology. Due to the characteristics described above, cellular therapy would be an alternative for tackling this disease and to reestablish the homeostasis of the infected tissues. Several studies have shown that MSC cells contribute in a paracrine way in tissue remodeling and control of inflammation ([@B22]). This is observed in parasitic diseases like *T. cruzi* ([@B11], [@B12], [@B23]) and *Schistosoma japonicum* ([@B24]). In some cases, it may have a direct effect, such as in the elimination of bacteria by inducing antimicrobial molecules, such aslipocalin 2, in the treatment of pneumonia caused by *Escherichia coli* infection ([@B25]), or by increasing ([@B26]) or employing IFN-gamma-activated MSCs that induce GTPases and guanylate-binding proteins that exhibit anti-parasitic action against *Toxoplasma gondii* and *Neospora caninum* ([@B27]).

In our study, we expected that the MSC treatment would reduce the parasite load and lesion size; however, treatments with MSC were not effective in cutaneous leishmaniasis models caused by *L. amazonensis* in BALB/c mice. The treatment with MSC by the intralesional and intravenous routes did not affect the lesion development (Figure [2](#F2){ref-type="fig"}A). Likewise, the i.l. injection of MSC did not change the number of parasites. However, treatment with MSC i.v. unexpectedly increased the parasite load (Figure [2](#F2){ref-type="fig"}B), which may suggest a systemic mechanism for this immunomodulation. In the spleen, we observed an increase of TCD8^+^ and TCD4^+^ cells secreting IL-10. The production of IL-10 by T cells is a possible mechanism associated to the pathogenesis of intravenous treatment with MSC that is not observed in the intralesional treatment.

The production of cytokines in leishmaniasis plays a key role in maintaining susceptibility or resistance to disease, with cytokines IL-10, IL-4, TGF-β and IFN-γ being more relevant. The IL-10, in our infection model, has been associated to pathogenesis. IL-10 plays a role in limiting IFN-γ production by CD4^+^ and NK T cells during *Leishmania* infection ([@B28], [@B29]). IL-10 has been able to suppress NO production and leishmanicidal activities in the macrophages, leading to the suppression of Th1 response, resulting in the continuous progression of infection in susceptible mice and preventing the elimination of *Leishmania* (sterile cure) in resistant mice ([@B29]). In mice infected with *L. amazonensis*, IL-10 partially contributes to the generation of poor immune response ([@B30]--[@B32]), which is the main factor that increases susceptibility in mice co-infected with phlebotomine saliva ([@B33]). Recently, it was demonstrated that IL-10 is exclusively produced by T cells and not by macrophage, and granulocytes are associated to pathogenesis in infections caused by *L. mexicana* ([@B34]). The literature indicates the pathogenic role of IL-10 production by T cells, similar what has been observed in our model in the group treated with MSC by i.v. route.

Padigel et al. ([@B35]) showed that IL-10 deficient BALB/c presented greater resistance to infection with *L. mexicana* and *L. amazonensis*. Increased resistance in IL-10^−/−^ mice is related to the production of IFN-γ and NO, although their high production does not negatively regulate the development of a Th2 response and is observed by the continuous production of IL-4. In these animals (IL-10^−/−^) anti-IL-4 monoclonal antibodies were used. However, this treatment did not promote resolution of the infection, which did not evidence a relation of IL-4 with the pathogenesis of the disease in this model. Regarding the levels of IL-4 and TGF-β in our study, we did not obtain significant differences among treated groups, which suggest the lack of pathogenesis modulation by IL-4 and TGF-β. The high concentration of IL-10 (Figure [5](#F5){ref-type="fig"}A) found in the footpad from mice treated with MCS by i.v. route might be negatively modulating the activation of the macrophages capable of eliminating *Leishmania*, which increases the parasite load (Figure [2](#F2){ref-type="fig"}B).

Previous observations have shown that parasite-specific Th1 cells promoted protective immunity to *Leishmania* ssp. infection ([@B36]). In addition, in the *L. amazonensis* infection, the role of IFN-γ *in vivo* was demonstrated as being essential to the control of lesion growth and parasite load in the chronic phase ([@B37]). Studies have shown that TCD8^+^ has a protective role in *L. amazonensis* infection, with effector mechanisms associated with TCD8^+^ producing INF-γ and perforin, to provide a protective immune response against parasites ([@B38]). The decrease of interferon-gamma production by TCD8^+^ in the MSC therapy by i.v. route associated with the increase of IL-10 could be directly related with the increase of parasite load and associated to pathogenesis. We observed a decrease of IFN-γ by TCD8^+^ cell in intralesional groups (PBS i.l. and MSC i.l.); however, without the increase of IL-10 level, the parasite load did not rise. The concomitant increase of IL-10 and decrease of IFN-γ may be the main factor of failure of our therapy.

Tregs are crucial maintaining the homeostasis and regulatory T cells do not serve only to prevent autoimmune diseases, but they can also generate suppressive immune responses that contribute to non-destruction of tissue infected by infectious agents ([@B39], [@B40]). In *L. amazonensis* infection, Treg cells are important in the control of lesion and parasite load in resistant mice model using C57BL6 ([@B41]); however, in BALB/c, the importance of Tregs in *L. amazonensis* is unknown. Ji et al. ([@B41]) showed in C57BL/6 that treatment with neutralizing murine Ab against TGF-β1 and IL-10 did not eliminate the effect of Treg cells *in vitro*, demonstrating the role of cell--cell interaction molecules and, at the same time, suggesting that IL-10 does not contribute to the protective effect.

Corroborating with the literature ([@B39], [@B40]), we observed that the groups treated with intravenous MSC presented an increase of regulatory T cells (CD4^+^ CD25^+^ FoxP3^+^) in the spleen (Figure [3](#F3){ref-type="fig"}B) in relation to their control (PBS i.v.). One of our hypotheses is that MSCs could induce regulatory T cells and control the pathology in *Leishmania* infection. MSC was able to perform the induction of Treg cells in the group treated with MSC by i.v. route in comparison with the control (PBS i.v.), but it did not protect against the lesion as expected based on C57BL6 mice model. The increase of Treg did not affect growth lesion, suggesting that lesion and Treg on BALB/c mice may not be related. Furthermore, Treg cells were not contra-protective either in our model, since the increase of Treg in intralesional groups (PBS i.l. and MSC i.l.) did not result in the increase of parasite load in the intralesional groups. Interesting, the groups that presented an increase of Treg (MSC i.v., PBS i.l., and MSC i.l.) showed a decrease of TCD8^+^ producing IFN-g, which suggests a possible function for Treg cells in BALB/c mice.

Mesenchymal stromal cell therapy through different administration routes (MSC i.l. and MSC i.v.) when compared with controls (PBS i.l. and i.v.) did not show protective effect against *L. amazonensis* infection. Therefore, more studies must be conducted to find therapies that are effective against leishmaniasis due to the toxicity of the current pharmacological treatments used in the clinical setting. Besides, as it has been reported, there are significant concerns in that the application of mesenchymal stem cell may suppress antimicrobial immunity with increased risk of infection ([@B42]).

Further studies are necessary to a complete understanding of the treatment using MSC against leishmaniasis. First, experimental cutaneous leishmaniasis was induced by *L. amazonensis* in BALB/c mice. Therefore, these results cannot be extrapolated to other leishmaniasis models, mouse strain or directly to the clinical scenario. Second, two doses of (10^5^) have been used and the effects of MSCs were evaluated 5 days after the second administration. Based on pilot studies, higher number of MSCs may increase the risk of embolism. Therefore, we decided to administer this dose twice. Nonetheless, in future studies with different doses, different ranges between MSC administration and analysis at earlier and later time points would be interesting. Third, MSCs from different sources exhibited distinct effects ([@B43], [@B44]); however, only MSC from bone marrow was used. Further studies are required using different MSC sources.

Conclusion {#S5}
==========

In the current murine model of cutaneous disease induced by *L. amazonensis*, bone marrow MSC therapy, in comparison with PBS, did not result in any significant difference in lesion progression, regardless of the administration route. Intravenous, but not intralesional administration of MSCs, increased the parasite load. BM-MSC therapy is not effective as a treatment against murine leishmaniasis.
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###### 

Phenotypic characterization of MSC. Bone marrow cells were obtained from the femur and tibia of BALB/c mice and maintained in culture until the fourth passage. About 1 × 10^6^ cells were characterized as MSCs according to the International Society of Cellular Consensus Therapy. Characterization of MSC cells was done using BD flow cytometry FACSCalibur. **(A)** CD 44 (Pecy5); **(B)** CD 49 (PE); **(C)** Sca-1 (APC); **(D)** CD 11b (FITC); **(E)** CD 45 (PE); **(F)** CD 34 (Effluor 660); and **(G)** MSC profile.
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